AR073396A1 - Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol - Google Patents
Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazolInfo
- Publication number
- AR073396A1 AR073396A1 ARP090103663A ARP090103663A AR073396A1 AR 073396 A1 AR073396 A1 AR 073396A1 AR P090103663 A ARP090103663 A AR P090103663A AR P090103663 A ARP090103663 A AR P090103663A AR 073396 A1 AR073396 A1 AR 073396A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- cycloalkyl
- alkoxy
- hydroxy
- Prior art date
Links
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 14
- 125000003545 alkoxy group Chemical group 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 7
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 6
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 6
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 abstract 5
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 5
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 hydroxy, carboxyl Chemical group 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son moduladores del FXR y pueden utilizarse como medicamentos utiles para disminuir la absorcion de colesterol, se disminuye el colesterol LDL y los triglicéridos y se reduce la ateroesclerosis inflamatoria. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es un anillo elegido entre el grupo formado por fenilo, naftilo y heteroarilo, dicho anillo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R2, R3, R4 y R5 se eligen con independencia entre si entre el grupo formado por hidrogeno, halogeno y alquilo inferior; R2' y R3' juntos así como R4' y R5' juntos se reemplazan por un doble enlace, o R2', R3', R4' y R5' son hidrogeno; R6 se elige entre el grupo formado por alquilo inferior, cicloalquilo, alcoxialquilo inferior, fenilo sin sustituir o fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior y ciano, fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano, heterociclilo y heteroarilo sin sustituir o heteroarilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R7 se elige entre el grupo formado por hidrogeno, -C(O)-NH-R8, -C(O)-R9, -S(O)2-R10 y -C(O)-OR11; R8 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R9 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R10 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi cuyo resto cicloalquilo está sustituido por carboxilo; y R11 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; o las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08165137 | 2008-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073396A1 true AR073396A1 (es) | 2010-11-03 |
Family
ID=41382044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103663A AR073396A1 (es) | 2008-09-25 | 2009-09-23 | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8153663B2 (es) |
| EP (1) | EP2346834B1 (es) |
| JP (1) | JP5450632B2 (es) |
| KR (1) | KR101444988B1 (es) |
| CN (1) | CN102164900B (es) |
| AR (1) | AR073396A1 (es) |
| AU (1) | AU2009295967A1 (es) |
| BR (1) | BRPI0919248A2 (es) |
| CA (1) | CA2736434A1 (es) |
| ES (1) | ES2443947T3 (es) |
| IL (1) | IL211674A0 (es) |
| MX (1) | MX2011002793A (es) |
| TW (1) | TW201020234A (es) |
| WO (1) | WO2010034657A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010034649A1 (en) * | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
| US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| JP5838497B2 (ja) * | 2010-05-25 | 2016-01-06 | シムライズ アーゲー | 抗セルライト有効成分としてのシクロヘキシルカルバメート化合物 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| KR101949251B1 (ko) | 2013-09-11 | 2019-02-18 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | B형간염바이러스 감염의 치료 방법 및 치료용 약학적 조성물 |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
| ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
| CN110944635A (zh) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | 用于减少附加体病毒的持久性和表达的方法和药物组合物 |
| PE20211733A1 (es) | 2019-01-11 | 2021-09-06 | Gruenenthal Chemie | Amidas de pirrolidina sustituidas |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| ES3014367T3 (en) | 2020-01-15 | 2025-04-22 | Inst Nat Sante Rech Med | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN113372276B (zh) * | 2021-05-25 | 2022-04-22 | 三峡大学 | 吲唑类衍生物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1974379A (en) * | 1932-10-12 | 1934-09-18 | Cinch Mfg Corp | Coupling device for hose and like connections |
| US1966325A (en) * | 1933-06-28 | 1934-07-10 | Verne E Welch | Pump |
| GB865341A (en) * | 1958-07-30 | 1961-04-12 | Bayer Ag | 5-benzene-sulphonamido-1-phenyl pyrazole derivatives |
| GB926327A (en) | 1960-05-13 | 1963-05-15 | Ici Ltd | New dyestuffs of the azostilbene series containing halopyrimidyl residues |
| GB1145544A (en) * | 1966-07-16 | 1969-03-19 | Polichimica Sap S P A | New tetrahydroindazoles |
| NL6707299A (es) * | 1966-07-16 | 1968-01-17 | ||
| WO2001098282A1 (en) | 2000-06-23 | 2001-12-27 | Takeda Chemical Industries, Ltd | Benzoxazepinones and their use as squalene synthase inhibitors |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| AR042067A1 (es) | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
| CN100448869C (zh) * | 2002-11-27 | 2009-01-07 | 拜尔药品公司 | 用于治疗糖尿病的苯胺基吡唑衍生物 |
| EP1698335A4 (en) * | 2003-12-26 | 2007-08-01 | Ono Pharmaceutical Co | AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR |
| WO2007056091A2 (en) | 2005-11-09 | 2007-05-18 | Abbott Laboratories | 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof |
| US20110195110A1 (en) * | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
-
2009
- 2009-09-15 ES ES09783046.7T patent/ES2443947T3/es active Active
- 2009-09-15 MX MX2011002793A patent/MX2011002793A/es active IP Right Grant
- 2009-09-15 WO PCT/EP2009/061966 patent/WO2010034657A1/en not_active Ceased
- 2009-09-15 EP EP09783046.7A patent/EP2346834B1/en not_active Not-in-force
- 2009-09-15 BR BRPI0919248A patent/BRPI0919248A2/pt not_active IP Right Cessation
- 2009-09-15 JP JP2011528291A patent/JP5450632B2/ja not_active Expired - Fee Related
- 2009-09-15 KR KR1020117009165A patent/KR101444988B1/ko not_active Expired - Fee Related
- 2009-09-15 CN CN200980137912.0A patent/CN102164900B/zh not_active Expired - Fee Related
- 2009-09-15 CA CA2736434A patent/CA2736434A1/en not_active Abandoned
- 2009-09-15 AU AU2009295967A patent/AU2009295967A1/en not_active Abandoned
- 2009-09-21 US US12/563,189 patent/US8153663B2/en not_active Expired - Fee Related
- 2009-09-22 TW TW098131981A patent/TW201020234A/zh unknown
- 2009-09-23 AR ARP090103663A patent/AR073396A1/es unknown
-
2011
- 2011-03-10 IL IL211674A patent/IL211674A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110059890A (ko) | 2011-06-07 |
| TW201020234A (en) | 2010-06-01 |
| JP2012503618A (ja) | 2012-02-09 |
| EP2346834A1 (en) | 2011-07-27 |
| AU2009295967A1 (en) | 2010-04-01 |
| ES2443947T3 (es) | 2014-02-21 |
| US8153663B2 (en) | 2012-04-10 |
| US20100076026A1 (en) | 2010-03-25 |
| JP5450632B2 (ja) | 2014-03-26 |
| IL211674A0 (en) | 2011-06-30 |
| MX2011002793A (es) | 2011-04-05 |
| KR101444988B1 (ko) | 2014-09-26 |
| CN102164900B (zh) | 2014-04-16 |
| WO2010034657A1 (en) | 2010-04-01 |
| EP2346834B1 (en) | 2013-11-20 |
| CN102164900A (zh) | 2011-08-24 |
| CA2736434A1 (en) | 2010-04-01 |
| BRPI0919248A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073396A1 (es) | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR120855A1 (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR060525A1 (es) | Piridin [3,4-b] pirazinonas. composiciones farmaceuticas | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR077413A1 (es) | Derivados piridin-4-ilo | |
| CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| AR078722A1 (es) | Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |